触媒制药公司

CPRX NASDAQ
3.790
+0.030
+0.80%
盘前: 3.770 -0.02 -0.53% 08:59 05/20 EDT
开盘
3.760
昨收
3.760
最高
3.850
最低
3.670
成交量
6
成交均量(3M)
276.85万
52周最高
6.16
52周最低
1.850
换手率
0.00%
市值
3.90亿
分时
5日
1月
3月
1年
5年

评论

暂无数据

相关股票

微牛行情栏目提供触媒制药公司 CPRX股票价格,触媒制药公司股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company's Firdapse is indicated for the treatments of lambert-eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). Firdapse consists of the phosphate salt of amifampridine. The Company has completed the Phase III trial of Firdapse. The Company's CPP-109 (vigabatrin) is a gamma-aminobutyric acid (GABA) aminotransferase inhibitor. CPP-109 is indicated for the treatment of Tourette's Disorder. The Company's CPP-115 is a GABA aminotransferase inhibitor. CPP-115 is indicated for the treatment of selected neurological indications, such as complex partial seizures and Tourette's Disorder, and epilepsy.
展开 >

最近浏览

名称
价格
涨跌幅